New studies showed that semaglutide (Ozempic) may help reduce the progression of kidney disease in people with type 2 diabetes, and it may also help protect kidney function in people who are overweight or obese with established cardiovascular disease
Timing: Typical research protocols administer capsules either fasted (30 minutes before food) or with light meal
However, more studies in larger populations are needed to better determine the risks and benefits and guide appropriate use of this medication, either independently or in conjunction with bariatric surgery
Nevertheless, it appears evident that lacking targeted policies may disrupt the transition process, leading to uneven benefits and the continuation of energy poverty (Bouzarovski and Simcock, 2017)
Koh A, De Vadder F, Kovatcheva-Datchary P, Backhed F